Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2015; 7(3): 521-531
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?
Xavier Adhoute, Guillaume Penaranda, Paul Castellani, Herve Perrier, Marc Bourliere
Xavier Adhoute, Paul Castellani, Herve Perrier, Marc Bourliere, Department of Hepatology, Hopital Saint-Joseph, 13285 Marseille, France
Guillaume Penaranda, Laboratoire Alphabio, Hôpital Européen, 13003 Marseille, France
Author contributions: Adhoute X and Perrier H collected data; Penaranda G performed statistical analyzes; Adhoute X, Bourliere M, Castellani P and Penaranda G analyzed data; Adhoute X and Bourliere M wrote the manuscript.
Conflict-of-interest: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Xavier Adhoute, Department of Hepatology, Hopital Saint-Joseph, 26 boulevard Louvain, 13285 Marseille, France. adhoute.xavier@neuf.fr
Telephone: +33 6-10-152948 Fax: +33 4-91-806912
Received: August 27, 2014
Peer-review started: August 28, 2014
First decision: September 19, 2014
Revised: October 2, 2014
Accepted: November 27, 2014
Article in press: November 27, 2014
Published online: March 27, 2015
Processing time: 216 Days and 13.1 Hours
Core Tip

Core tip: Despite its widespread use in hepatocellular carcinoma, the indications for Transarterial chemoembolization are still debated. There are no rules about the treatment modalities or strategy to follow. To overcome these difficulties, a simple scoring system, including prognostic variables, designed as a decision support, would be useful. Deciding when we have to move from a loco-regional treatment to a systemic option is matter of significant interest, particularly since sorafenib now provides us with a solution.